Targeting Cellular Metabolism With CPI-613 Sensitizes Pancreatic Cancer Cells to Radiation TherapyHusain Yar Khan, Asfar S. Azmi, Mohammed Najeeb Al Hallak et al.|Advances in Radiation Oncology|2022Cited by 20
Abstract CT080: A phase I study of CPI-613 (devimistat) in combination with chemoradiation in patients with pancreatic ductal adenocarcinomaMandana Kamgar, William A. Hall, Husain Yar Khan et al.|Cancer Research|2024Cited by 3
Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal AdenocarcinomaMandana Kamgar, Thomas McFall, G. Aaron Hobbs et al.|Cancer Research|2025Cited by 3